Pacific Point Advisors LLC bought a new stake in shares of ResMed Inc. (NYSE:RMD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,306 shares of the medical equipment provider's stock, valued at approximately $1,276,000.
Other hedge funds also recently modified their holdings of the company. Howard Capital Management Inc. boosted its position in ResMed by 5.3% in the fourth quarter. Howard Capital Management Inc. now owns 900 shares of the medical equipment provider's stock worth $206,000 after purchasing an additional 45 shares during the last quarter. Faithward Advisors LLC increased its position in shares of ResMed by 4.3% during the 4th quarter. Faithward Advisors LLC now owns 1,279 shares of the medical equipment provider's stock valued at $292,000 after purchasing an additional 53 shares during the last quarter. Meiji Yasuda Life Insurance Co increased its position in shares of ResMed by 4.6% during the 4th quarter. Meiji Yasuda Life Insurance Co now owns 1,356 shares of the medical equipment provider's stock valued at $310,000 after purchasing an additional 60 shares during the last quarter. HighPoint Advisor Group LLC boosted its holdings in ResMed by 2.6% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,570 shares of the medical equipment provider's stock valued at $610,000 after acquiring an additional 64 shares during the period. Finally, Commerce Bank lifted its holdings in ResMed by 1.1% in the 4th quarter. Commerce Bank now owns 6,448 shares of the medical equipment provider's stock worth $1,475,000 after buying an additional 73 shares during the period. Hedge funds and other institutional investors own 54.98% of the company's stock.
Insider Activity
In other news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $227.71, for a total transaction of $455,420.00. Following the completion of the sale, the director now owns 75,218 shares in the company, valued at $17,127,890.78. This represents a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Kaushik Ghoshal sold 9,745 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $239.31, for a total value of $2,332,075.95. Following the sale, the insider now owns 9,725 shares of the company's stock, valued at $2,327,289.75. This trade represents a 50.05% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,949 shares of company stock valued at $11,822,260. 0.71% of the stock is currently owned by company insiders.
ResMed Stock Up 1.4%
Shares of NYSE RMD traded up $3.42 during midday trading on Tuesday, hitting $246.26. 1,056,206 shares of the company's stock were exchanged, compared to its average volume of 1,050,465. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. ResMed Inc. has a twelve month low of $179.42 and a twelve month high of $263.05. The company has a market cap of $36.11 billion, a PE ratio of 29.07, a P/E/G ratio of 1.53 and a beta of 0.78. The firm's fifty day simple moving average is $228.30 and its 200-day simple moving average is $234.10.
ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, topping the consensus estimate of $2.36 by $0.01. The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.28 billion. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The firm's revenue was up 7.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.13 earnings per share. Research analysts predict that ResMed Inc. will post 9.47 EPS for the current fiscal year.
ResMed Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, May 8th. ResMed's payout ratio is currently 23.79%.
Wall Street Analysts Forecast Growth
RMD has been the topic of several research reports. Wall Street Zen lowered ResMed from a "buy" rating to a "hold" rating in a research report on Saturday. JPMorgan Chase & Co. boosted their price target on ResMed from $286.00 to $290.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Royal Bank of Canada boosted their price objective on ResMed from $247.00 to $255.00 and gave the company a "sector perform" rating in a research report on Thursday, April 24th. Citigroup upgraded ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. Finally, Stifel Nicolaus decreased their price objective on ResMed from $250.00 to $240.00 and set a "hold" rating on the stock in a research report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $259.33.
View Our Latest Research Report on RMD
ResMed Profile
(
Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Further Reading

Before you consider ResMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.
While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report